Richard S. Shames

Health Technology

Consumer Services

Active connections

Name	Gender	Age	Linked companies	Collaboration
Lewis Williams	M	74	PROTAGONIST THERAPEUTICS, INC.	7 years
William Waddill	M	67	PROTAGONIST THERAPEUTICS, INC.	8 years
Chirfi Guindo	M	58	MERCK & CO., INC.	13 years
Bryan Giraudo	M	48	PROTAGONIST THERAPEUTICS, INC.	6 years
Dalton Smart	M	58	MERCK & CO., INC.	15 years
Carter J. King	M	52	PROTAGONIST THERAPEUTICS, INC.	6 years
Richard DeLuca	M	61	MERCK & CO., INC.	13 years
Ashok Bhandari	M	-	PROTAGONIST THERAPEUTICS, INC.	7 years
Sanat Chattopadhyay	M	-	MERCK & CO., INC.	15 years
Pamela Eisele	F	-	MERCK & CO., INC.	15 years
Denise Williams	F	-	MERCK & CO., INC.	15 years
Suneel Gupta	M	66	PROTAGONIST THERAPEUTICS, INC.	5 years
Mohammad Masjedizadeh	M	-	PROTAGONIST THERAPEUTICS, INC.	7 years

Connections Chart

Multi-company connection

Former connections

Name	Gender	Age	Linked companies	Collaboration
Faheem Hasnain	M	65	Abbott Biotherapeutics Corp. Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA.	2 years
Timothy Shannon	M	65	Aldea Pharmaceuticals, Inc. Aldea Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aldea Pharmaceuticals, Inc. develops novel enzyme activators to enhance the removal of toxic aldehydes. It targets Aldehyde metabolism dysfunction which is associated with a variety of diseases from acute alcohol toxicity to orphan indications such as Fanconi anemia. The company was founded by Daria Mochly-Rosen, Che-Hong Chen and Wenjin Yang in 2011 and is headquartered in Redwood City, CA.	3 years
Richard Clark	M	77	MERCK & CO., INC.	6 years
Fred Hassan	M	78	MERCK & CO., INC.	6 years
Carlos Eduardo Represas de Almeida	M	78	MERCK & CO., INC.	-
Samuel Saks	M	69	PROTAGONIST THERAPEUTICS, INC.	-
Julie Gerberding	M	69	MERCK & CO., INC.	-
Thomas O'Neil	M	59	PROTAGONIST THERAPEUTICS, INC.	3 years
Bradford Goodwin	M	69	Abbott Biotherapeutics Corp. Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA.	2 years
Michael Nally	M	48	MERCK & CO., INC.	10 years
Thomas Robert Cech	M	76	MERCK & CO., INC.	-
Thomas Shenk	M	77	MERCK & CO., INC.	11 years
Harry R. Jacobson	M	76	MERCK & CO., INC.	3 years
Jean-Marie Canan	M	68	MERCK & CO., INC.	5 years
Herbert Cross	M	52	Abbott Biotherapeutics Corp. Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA.	-
Steven Goldstone	M	78	MERCK & CO., INC.	6 years
Francis Sarena	M	53	Abbott Biotherapeutics Corp. Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA.	2 years
Caroline Dorsa	F	64	MERCK & CO., INC.	22 years
Julie Grant	F	41	PROTAGONIST THERAPEUTICS, INC.	2 years
Sarah Noonberg	M	56	PROTAGONIST THERAPEUTICS, INC.	6 years
William N. Kelley	M	84	MERCK & CO., INC.	-
Jeffrey Chodakewitz	M	68	MERCK & CO., INC.	4 years
D. Gilliland	M	69	MERCK & CO., INC.	4 years
Yan Li	F	50	MERCK & CO., INC.	4 years
Graham Lumsden	M	64	MERCK & CO., INC.	26 years
Gwen R. Carscadden	F	62	Abbott Biotherapeutics Corp. Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA.	2 years
Rasappa Arumugham	M	73	MERCK & CO., INC.	2 years
Mark Shearman	M	62	MERCK & CO., INC.	3 years
Stephen Farrand	M	-	MERCK & CO., INC.	6 years
Terrie Curran	F	55	MERCK & CO., INC.	4 years
Timothy Murphy	M	56	MERCK & CO., INC.	4 years
Sachin Jain	M	43	MERCK & CO., INC.	2 years
Doron Ben-Ami	M	72	MERCK & CO., INC.	5 years
Maarten van der Linden	M	55	MERCK & CO., INC.	4 years
Lucio Tozzi	M	60	PROTAGONIST THERAPEUTICS, INC.	4 years
Jens Renstrup	M	59	MERCK & CO., INC.	8 years
Arnaub Chatterjee	M	-	MERCK & CO., INC.	5 years
Gerard Cunningham	M	-	MERCK & CO., INC.	1 years
Srikanth Venkatraman	M	-	MERCK & CO., INC.	4 years
Carlos Lugo	M	-	MERCK & CO., INC.	2 years
Mark Bach	M	67	MERCK & CO., INC.	17 years
Yanni Souroutzidis	M	-	MERCK & CO., INC.	2 years
Rafael Torgovicky	M	-	MERCK & CO., INC.	2 years
Francesco Maria Lavino	M	51	MERCK & CO., INC.	2 years
Sheldon Koenig	M	58	MERCK & CO., INC.	6 years
Pernilla Sandwall	F	61	MERCK & CO., INC.	8 years
Yao Lee	M	54	MERCK & CO., INC.	3 years
Ernesto Aycardi	M	61	MERCK & CO., INC.	11 years
Alexis Ji	M	-	MERCK & CO., INC.	5 years
Hugo Wahnish	M	-	MERCK & CO., INC.	18 years
Geralyn S. Ritter	F	-	MERCK & CO., INC.	8 years
Lawrence D. Senour	M	59	MERCK & CO., INC.	-
Vijay Tammara	M	64	MERCK & CO., INC.	6 years
Andrew Guggenhime	M	55	Abbott Biotherapeutics Corp. Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA.	2 years
Bridgette Heller	F	62	MERCK & CO., INC.	5 years
Dennis Erb	M	-	MERCK & CO., INC.	-
Richard S. Bowles	M	72	MERCK & CO., INC.	-
Evgeny Zaytsev	M	56	Aldea Pharmaceuticals, Inc. Aldea Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aldea Pharmaceuticals, Inc. develops novel enzyme activators to enhance the removal of toxic aldehydes. It targets Aldehyde metabolism dysfunction which is associated with a variety of diseases from acute alcohol toxicity to orphan indications such as Fanconi anemia. The company was founded by Daria Mochly-Rosen, Che-Hong Chen and Wenjin Yang in 2011 and is headquartered in Redwood City, CA.	-
Jaisim Shah	M	63	Abbott Biotherapeutics Corp. Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA.	1 years
Margaret McGlynn	F	64	MERCK & CO., INC.	11 years
Gary Lyons	M	73	Abbott Biotherapeutics Corp. Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA.	2 years
David Parkinson	M	73	Abbott Biotherapeutics Corp. Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA.	2 years
Samuel O. Thier	M	86	MERCK & CO., INC.	16 years
Pam Cheng	F	53	MERCK & CO., INC.	5 years
Ted Llana	M	60	Abbott Biotherapeutics Corp. Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA.	-
Stefan Oschmann	M	66	MERCK & CO., INC.	20 years
James Christopher Scalet	M	65	MERCK & CO., INC.	9 years
Raul E. Kohan	M	71	MERCK & CO., INC.	1 years
Mark McCamish	M	72	Abbott Biotherapeutics Corp. Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA.	1 years
Anthony Rimac	M	60	Aldea Pharmaceuticals, Inc. Aldea Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aldea Pharmaceuticals, Inc. develops novel enzyme activators to enhance the removal of toxic aldehydes. It targets Aldehyde metabolism dysfunction which is associated with a variety of diseases from acute alcohol toxicity to orphan indications such as Fanconi anemia. The company was founded by Daria Mochly-Rosen, Che-Hong Chen and Wenjin Yang in 2011 and is headquartered in Redwood City, CA.	1 years
Franklin Clyburn	M	59	MERCK & CO., INC.	13 years
Peter Honig	M	67	MERCK & CO., INC.	7 years
Glenn Williams	M	-	MERCK & CO., INC.	10 years
Roger Pomerantz	M	67	MERCK & CO., INC.	3 years
Bruno Strigini	M	63	MERCK & CO., INC.	5 years
Eric Schadt	M	59	MERCK & CO., INC.	8 years
Aaron Dent	M	-	MERCK & CO., INC.	6 years
David A. Esposito	M	55	MERCK & CO., INC.	13 years
Piotr Bobrowicz	M	-	MERCK & CO., INC.	-
David Monteith	M	60	MERCK & CO., INC.	5 years
Daniel Bouthillier	M	-	MERCK & CO., INC.	16 years
Christopher Garland	M	-	MERCK & CO., INC.	-
Cuong Viet Do	M	58	MERCK & CO., INC.	3 years
Ami Knoefler	F	-	Abbott Biotherapeutics Corp. Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA.	1 years
Graeme Bell	M	57	MERCK & CO., INC.	2 years
Michael Holston	M	61	MERCK & CO., INC.	6 years
Milenko Cicmil	M	-	MERCK & CO., INC.	-

Statistics

Country	Connections	% of total
United States	100	100.00%

Age of Connections

Active

Past

Male

Female

Members of the board

Executives

Origin of connections